Central antinociceptive effects of lysine-vasopressin and an analogue.
Vasopressin (VP) neurons project to extrahypothalamic sites involved in pain perception, including the substantia gelatinosa of the spinal cord as well as the trigeminal and vagus nerves. Previous studies have reported antinociceptive activity following intracerebroventricular (ICV) or subcutaneous (SC) VP injections (16-100 microgram) on the tail-flick test while hyperalgesia has been observed in rats either genetically deficient in VP or treated with antisera to VP. The present study investigated whether nanogram (ng) doses of lysine-vasopressin (LVP) and a VP analogue with prolonged activity increased tail-flick latencies and flinch-jump thresholds following ICV or SC injections. LVP (150 and 500 ng, ICV) significantly increased tail-flick latencies while the analogue 1-deamino-(8-Lys-N epsilon-(Gly-Gly-Gly))-VP (500 ng, ICV) produced more powerful and prolonged analgesia. In contrast, latencies were not increased by SC injections of LVP (150-1500 ng). Further, flinch-jump thresholds were affected minimally by either ICV or SC LVP injections. These data suggest a role for VP in pain modulation and a central site of this action.
D000698:Analgesia; D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D007276:Injections, Intraventricular; D007279:Injections, Subcutaneous; D007700:Kinetics; D008236:Lypressin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D051381:Rats; D011919:Rats, Inbred Strains
D008236:Lypressin; C036012:1-deamino-triglycyl-8-lysine-vasopressin